使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and welcome to the Acadia Healthcare Fourth Quarter and Full Year 2023 Earnings Conference Call. (Operator Instructions) Please note, today's event is being recorded.
各位好,歡迎參加 Acadia Healthcare 2023 年第四季暨全年財報電話會議。(接線員指示)請注意,今日活動將進行錄音。
I'd now like to turn the conference over to Gretchen Hommrich. Please go ahead.
現在我想把會議交給 Gretchen Hommrich。請開始。
Gretchen Hommrich - VP of IR
Gretchen Hommrich - VP of IR
Good morning, and welcome to Acadia's Fourth Quarter 2023 Conference Call. I'm Gretchen Hommrich, Vice President of Investor Relations for Acadia. Here with me today are Chris Hunter, Acadia's Chief Executive Officer; and Heather Dixon, our Chief Financial Officer.
早安,歡迎參加 Acadia 2023 年第四季電話會議。我是 Gretchen Hommrich,Acadia 投資人關係副總裁。今天與我一同出席的有 Acadia 執行長 Chris Hunter,以及我們的財務長 Heather Dixon。
I'll first provide you with our safe harbor before turning the call over to Chris. To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link.
在把電話交給 Chris 之前,我先提供我們的安全港聲明。若今日電話會議中討論任何非 GAAP 財務衡量指標,您也可在我們網站上,透過「投資人」連結查看昨日新聞稿,找到該指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。
This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2024 and beyond.
本次電話會議可能包含《1995 年私人證券訴訟改革法》所定義的前瞻性陳述,其中包括但不限於關於 Acadia 對 2024 年及其後預期的季度與年度財務表現之陳述。
You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's fourth quarter news release. And consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements.
特此提醒您,這些陳述可能受到多項重要因素影響,包括但不限於 Acadia 向美國證券交易委員會提交之文件以及公司第四季新聞稿中所列因素。因此,實際營運與結果可能與前瞻性陳述中討論的結果存在重大差異。
At this time, I would like to turn the conference call over to our Chief Executive Officer, Chris Hunter, for opening remarks.
此刻,我想把電話會議交給我們的執行長 Chris Hunter 進行開場致詞。
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Thank you, Gretchen, and good morning, everyone. Thank you for being with us for Acadia's Fourth Quarter 2023 Conference Call.
謝謝你,Gretchen,各位早安。感謝各位參加 Acadia 2023 年第四季電話會議。
Our strong fourth quarter capped off another outstanding year of solid financial and operational performance for Acadia. Our team has continued to execute on our strategy with positive results across our 4 lines of business. For the full year 2023, we reported robust annual revenue growth of 12.2%, adjusted EBITDA growth of 13.1% and adjusted EPS growth of 14.3% as compared to 2022, excluding income from the provider relief fund recognized in both periods.
我們強勁的第四季表現,為 Acadia 又一個在財務與營運上穩健出色的年度畫下句點。我們的團隊持續執行策略,並在四大業務線皆取得正向成果。2023 全年,我們在排除兩期皆認列之「提供者紓困基金」收入後,相較 2022 年,年營收成長 12.2%、調整後 EBITDA 成長 13.1%、調整後 EPS 成長 14.3%。
Moving to our fourth quarter results. Our same facility revenue increased 10.3% compared with the fourth quarter of last year, with the increase driven by both rate improvements and patient day growth. We were also pleased to see consistent improvement in our labor trends throughout 2023.
接著談第四季結果。我們的同店營收較去年第四季成長 10.3%,成長動能同時來自費率改善與病人日數增加。我們也很高興看到 2023 年全年的人力趨勢持續改善。
Our wage inflation decreased from a peak of 8% in the fourth quarter of 2022 to below 5% in the fourth quarter of 2023, which is an improvement of over 300 basis points. In addition to improvements in the external labor market, our initiatives to drive higher employee engagement and more operational consistency in our facilities have enhanced our ability to attract and retain employees in a competitive market.
我們的薪資通膨自 2022 年第四季 8% 的高峰,下降至 2023 年第四季的 5% 以下,改善超過 300 個基點。除了外部勞動市場改善之外,我們推動更高員工敬業度與提升院區營運一致性的各項措施,也強化了我們在競爭激烈的市場中招募與留任員工的能力。
We have focused on more extensive clinical training for new staff and more intentional sharing of best practices while at the same time, investing in technology tools that support Acadia employees and clinicians across our 253 facilities. We've also had an emphasis on benefits and progressive career development opportunities for employees at all levels of our facilities. Efforts to improve retention and hiring are evident in our ability to support annual patient day growth of over 5% to ensure we provide high-quality patient care. Our team has done an outstanding job in meeting the higher patient demand and effectively managing operations.
我們著重於為新進人員提供更完整的臨床訓練,並更有系統地分享最佳實務;同時也投資科技工具,以支援 Acadia 在 253 家機構中的員工與臨床人員。我們亦強調各院區各層級員工的福利與更具前瞻性的職涯發展機會。提升留任與招募的努力,反映在我們具備支撐全年病人日數成長逾 5% 的能力,確保提供高品質的病患照護。我們的團隊在因應更高的病患需求並有效管理營運方面表現卓越。
During the fourth quarter, we continued to extend our market reach and add capacity through each one of our 5 defined growth pathways as follows: in support of our first pathway facility expansions, we added 98 beds during the fourth quarter for a total of 302 beds that additions to existing facilities in 2023. We are pleased that this was in line with our stated goal to add approximately 300 beds.
在第四季,我們持續透過五項明確的成長途徑擴大市場觸及並增加產能,具體如下:為支持第一項途徑—院區擴建,我們在第四季新增 98 張床位,使 2023 年既有院區新增床位總數達 302 張。我們很高興這與我們先前提出約新增 300 張床位的目標一致。
For our second pathway, we remained focused on developing wholly owned de novo facilities in underserved markets for behavioral health care services. During the fourth quarter, we opened the newly renovated 101-bed adult hospital, Montrose Behavioral Health Hospital in Chicago, Illinois. We have also completed construction on our 80-bed inpatient hospital, Coachella Valley Behavioral Health, located in Indio, California, which we expect to open later this year.
就第二項途徑而言,我們持續聚焦於在行為健康照護服務不足的市場,開發全資持有的全新(de novo)院區。第四季期間,我們在伊利諾州芝加哥開設了全新整修完成、101 床的成人醫院 Montrose Behavioral Health Hospital。我們也已完成位於加州印第奧(Indio)的 80 床住院醫院 Coachella Valley Behavioral Health 的建造,預計將於今年稍晚開幕。
Our CTC service line offers comprehensive care for patients who are affected by opioid use disorder or OUD. We opened 2 new CTC locations in the fourth quarter, bringing our total to 6 CTC opened in 2023, in line with our goal for the year, and we remain focused on accelerating our CTC expansion by opening up to 14 CTCs in 2024.
我們的 CTC 服務線為受阿片類藥物使用障礙(OUD)影響的病患提供全面照護。我們在第四季新開設 2 個 CTC 據點,使 2023 年新開設 CTC 總數達 6 個,符合我們年度目標;同時我們仍聚焦於加速 CTC 擴張,目標在 2024 年最多開設 14 個 CTC。
The opioid epidemic continues to intensify with approximately 9 million Americans misusing opioids in the past year in new, more potent drugs continuing to emerge. In fact, some experts believe that we have now entered the fourth wave of the opioid epidemic as drug users have now evolved from prescription drugs in the first wave to heroin and then to fentanyl in the second and third waves and now to polysubstances that include fentanyl mixed with substances such as cocaine and methamphetamine.
阿片類藥物疫情持續加劇,過去一年約有 900 萬名美國人濫用阿片類藥物,且新的、更強效的藥物不斷出現。事實上,有些專家認為我們已進入阿片類藥物疫情的第四波:用藥者已從第一波的處方藥,演變到第二、第三波的海洛因與芬太尼,如今則轉向包含芬太尼與可卡因、甲基安非他命等物質混用的多重物質(polysubstances)。
According to a recent report, nearly 93% of fentanyl positive urine samples contained additional substances. Methamphetamine, a highly addictive drug was found in 60% of fentanyl positive tests last year, which is an 875% increase since 2015. As we continue to expand this important area of our business, we remain focused on driving strong clinical outcomes, improving access and delivering an exceptional patient experience spanning our traditional opioid treatment programs or OTPs to mobile vans and telehealth solutions.
根據近期報告,近 93% 的芬太尼陽性尿液樣本含有其他物質。高度成癮的甲基安非他命在去年 60% 的芬太尼陽性檢測中被發現,較 2015 年增加 875%。在我們持續擴展此一重要業務領域之際,我們仍專注於推動強勁的臨床成效、改善可近性,並在從傳統阿片治療計畫(OTP)到行動車與遠距醫療解決方案的全範圍中,提供卓越的病患體驗。
But regardless of how patients come to Acadia for OUD treatment, quality is always a top priority and we were proud to have recently received a quality score of over 99% across 13 measures by the Commission on Accreditation of Rehabilitation Facilities or CARF.
但無論病患以何種方式來到 Acadia 接受 OUD 治療,品質永遠是首要之務;我們也很自豪近期獲得復健設施認證委員會(CARF)就 13 項衡量指標給予超過 99% 的品質評分。
For our third growth pathway, we are working to expand our reach through our joint ventures. Notably, Acadia is considered an attractive partner of choice for establishing relationships with premier health systems across the country. As the leading pure-play behavioral health provider, we bring the clinical expertise and experience and a proven ability to expand behavioral health care in more communities. Today, Acadia has 21 joint venture partnerships for 22 hospitals with 11 hospitals already in operation and 11 additional hospitals expected to open over the next few years.
就第三項成長途徑而言,我們正透過合資企業擴大觸及範圍。值得一提的是,Acadia 被視為與全美頂尖醫療體系建立合作關係時極具吸引力的首選夥伴。作為領先的純行為健康服務提供者,我們具備臨床專業與經驗,並擁有在更多社區擴展行為健康照護的成熟能力。如今,Acadia 擁有 21 個合資夥伴關係、涵蓋 22 家醫院,其中 11 家已投入營運,另有 11 家預計在未來幾年陸續開幕。
In early January 2024, Acadia announced a joint venture partnership with Ascension Seton, one of the nation's leading integrated health care systems. The joint venture will focus on expanding Acadia's current operations across Creek Hospital in Austin, Texas, by constructing a 106-bed expansion of our existing acute behavioral hospital.
2024 年 1 月上旬,Acadia 宣布與 Ascension Seton(全美領先的整合式醫療體系之一)建立合資夥伴關係。該合資將聚焦於擴大 Acadia 在德州奧斯汀 Creek Hospital 現有急性行為健康醫院的營運,並興建 106 床的擴建工程。
This is the company's second joint venture partnership with Ascension and follows the opening in 2020 of Ascension Saint Thomas, a behavioral health facility in Nashville. Our new partnership with Ascension is a testament to the strength of our relationship and reflects our solid track record of clinical, operational and financial outcomes with our joint venture partners.
這是公司與 Ascension 的第二個合資夥伴關係,並延續 2020 年於納許維爾開設 Ascension Saint Thomas 行為健康機構的合作。我們與 Ascension 的新合作證明了雙方關係的穩固,也反映我們與合資夥伴在臨床、營運與財務成果方面的良好實績。
The new partnership will expand access to behavioral health care in Austin and its surrounding communities. The joint venture hospital will be in close proximity to Ascension Seton hospitals and will be one of the training sites for students, residents and fellows from the Dell Medical School at the University of Texas at Austin.
這項新合作將擴大奧斯汀及其周邊社區對行為健康照護的可近性。該合資醫院將鄰近 Ascension Seton 醫院群,並將成為德州大學奧斯汀分校 Dell 醫學院學生、住院醫師與研究員(fellows)的其中一個訓練據點。
Together with our JV partners, we have a shared commitment to providing access to high-quality compassionate behavioral health care and supporting the critical need in our local communities. Joint ventures will continue to play an important role in Acadia's future growth, and we remain excited about the opportunities to work with other leading providers in attractive geographies.
我們與合資夥伴共同承諾,提供可近的高品質、富同理心的行為健康照護,並支持在地社區的迫切需求。合資企業將持續在 Acadia 未來成長中扮演重要角色,我們也對於在具吸引力的地理區域與其他領先提供者合作的機會保持期待。
For our fourth pathway, we continue to look for acquisitions that support our growth objectives and meet the criteria of our capital allocation strategy. Last week, we closed on our previously announced acquisition of Turning Point Centers, a 76-bed specialty provider of substance use disorder and primary mental health treatment services that supports the Salt Lake City, Utah, metropolitan market. This acquisition completes the continuum of care in that market and represents the first market where Acadia has all 4 service lines present.
就第四項途徑而言,我們持續尋找能支持成長目標、並符合資本配置策略標準的併購機會。上週,我們完成先前已公告的 Turning Point Centers 收購案;該公司為一家具 76 床的專科服務提供者,提供物質使用障礙與主要心理健康治療服務,服務範圍涵蓋猶他州鹽湖城都會市場。此項收購完善了該市場的照護連續體,也代表這是 Acadia 首個同時具備四大服務線的市場。
Our fifth and final growth pathway, extending the continuum of care is important to our clinical strategy. One of the key focus areas of this pathway is expanding our partial hospitalization programs or PHP in intensive outpatient programs, IOP, that can provide 4 to 6 hours of care per day. The majority of our acute and specialty patients can clinically benefit from these programs as they offer a step-down level of care after discharge from a high acuity stay, but also enable patients to step up again in acuity as their needs change. This not only improves clinical outcomes but also enhances the overall patient experience.
我們的第五個也是最後一個成長途徑——延伸照護連續體——對我們的臨床策略至關重要。此途徑的關鍵聚焦領域之一,是擴大我們的部分住院計畫(PHP)或密集門診計畫(IOP),可提供每日 4 至 6 小時的照護。我們多數急性與專科患者在臨床上都能從這些計畫中受益,因為它們在患者自高強度住院出院後提供降階照護,但也能在患者需求改變時,讓其再度升階至更高強度的照護。這不僅改善臨床結果,也提升整體病患體驗。
We added 13 outpatient programs during the fourth quarter, bringing Acadia's total to 39 outpatient programs added during calendar 2023. We are also working to increase the opportunity for our patients to utilize PHP, IOP services as only a portion of our clinically eligible patients stepped down to PHP, IOP care post discharge today.
我們在第四季新增了 13 個門診計畫,使 Acadia 於 2023 年曆年新增的門診計畫總數達到 39 個。我們也正致力於提高患者使用 PHP、IOP 服務的機會,因為目前出院後降階至 PHP、IOP 照護的臨床適格患者僅占一部分。
As we stated at our Investor Day in December of 2022, we expected an acceleration of our bed additions in 2024, and we are pleased to deliver on that goal this year by adding approximately 1,200 beds. This will include approximately 400 bed additions to existing facilities, which is a step up from our historical average of 300 bed additions to existing facilities. We continued to make progress on our new facilities that will open in Florida, California, Michigan, Texas, Colorado, Arizona and Wisconsin in 2024.
正如我們在 2022 年 12 月投資人日所述,我們預期 2024 年的床位新增將加速;我們很高興今年能達成該目標,新增約 1,200 張床位。其中約 400 張床位將新增於既有設施,較我們過往平均每年在既有設施新增 300 張床位有所提升。我們也持續推進將於 2024 年在佛羅里達、加州、密西根、德州、科羅拉多、亞利桑那與威斯康辛開幕的新設施。
Additionally, we plan to open up to 14 new CTC locations in 2024. As we continue to extend our market reach, patient safety and quality patient care remain our top priorities for delivering the best possible outcome for our patients. Quality is foundational to every aspect of the work we do at Acadia and drives operational effectiveness.
此外,我們計畫在 2024 年最多新開設 14 個 CTC 據點。隨著我們持續擴大市場觸及範圍,病患安全與高品質病患照護仍是我們的首要優先事項,以為患者帶來最佳可能的結果。品質是 Acadia 所做每一項工作的基石,並驅動營運效能。
Our quality initiatives are focused on providing industry-leading care to the patients we serve daily, supporting our Acadia teammates through leadership development and thorough competency-based training, building proactive tools for identifying risks and opportunities and utilizing technology, including a quality data platform and predictive analytics to monitor our progress.
我們的品質倡議聚焦於:為我們每日服務的患者提供業界領先的照護;透過領導力發展與完善的能力本位訓練支持 Acadia 團隊成員;建立可主動辨識風險與機會的工具;並運用科技(包括品質數據平台與預測分析)來監測我們的進展。
We have made significant technology investments in 2023 to further strengthen our core capabilities enable us to deliver stronger clinical outcomes. Our recent investments in electronic medical records have helped support our clinical staff with improved retention, employee satisfaction and workflow efficiencies. Our optimized EMR, which has been implemented using the insight from several of our medical nursing and clinical leaders ensures we translate the best of behavioral science into practice at every bed side.
我們在 2023 年進行了重大科技投資,以進一步強化核心能力,使我們能交付更佳的臨床結果。我們近期在電子病歷(EMR)方面的投資,有助於支持臨床人員,提升留任率、員工滿意度與工作流程效率。我們優化後的 EMR 在導入時採納了多位醫師、護理與臨床領導者的洞見,確保我們能在每一張病床旁把行為科學的最佳實務落地。
In addition, we have now implemented patient monitoring technology in 53 facilities promoting higher touch care for fewer incidents and enhance patient safety. These investments in our core infrastructure, combined with the EMR and patient care technology, provide access to better data to measure outcomes and provide a framework for value-based care. The ability to measure and demonstrate these outcomes is important for collaborating with payers.
此外,我們目前已在 53 家機構導入病患監測技術,以促進更高接觸度的照護、降低事件發生並提升病患安全。這些對核心基礎設施的投資,結合 EMR 與病患照護技術,可取得更好的數據以衡量結果,並為價值導向照護提供架構。能夠衡量並展示這些結果,對於與付款方合作相當重要。
We are proud of our impressive growth and progress over the past year and look forward to the significant opportunities ahead for Acadia to extend our market reach to serve even more patients in 2024. Our strategic priorities will focus on accelerating facility growth, expanding services across the care continuum, strengthening our capabilities and strategically leveraging technology to enhance patient care and improve clinical outcomes, all with the focus on delivering the highest quality patient care.
我們為過去一年令人印象深刻的成長與進展感到自豪,並期待 2024 年 Acadia 在擴大市場觸及、服務更多患者方面的重大機會。我們的策略重點將聚焦於加速設施成長、在照護連續體上擴展服務、強化能力,並策略性運用科技以提升病患照護與改善臨床結果,一切以提供最高品質的病患照護為核心。
We are well positioned to meet our objectives with our financial strength, scale and committed employees and clinicians who work hard every day to address the nation's critical need for safe, quality treatment for mental health and substance use issues.
憑藉我們的財務實力、規模,以及每天努力工作的敬業員工與臨床人員,我們已具備良好條件達成目標,以回應全國對心理健康與物質使用問題之安全、高品質治療的迫切需求。
At this time, I will now turn the call over to Heather to discuss our financial results for the quarter and 2024 guidance.
接下來,我將把電話會議交給 Heather,請她說明本季財務結果與 2024 年展望指引。
Heather Dixon - CFO
Heather Dixon - CFO
Thanks, Chris, and good morning, everyone. Our fourth quarter financial performance reflects strong and consistent growth in our business in 2023. We achieved solid top line growth with $742.8 million in revenue for the quarter, up 10% over the fourth quarter of last year. Our same-facility revenue grew 10.3% compared with the fourth quarter of 2022, which included an increase in revenue per patient day of 7.1% and patient days growth of 2.9%.
謝謝你,Chris,各位早安。我們第四季的財務表現反映出 2023 年業務強勁且持續一致的成長。本季營收為 7.428 億美元,較去年第四季成長 10%,實現穩健的營收成長。同店營收較 2022 年第四季成長 10.3%,其中每病患日營收增加 7.1%,病患日數成長 2.9%。
The company recorded income related to the Provider Relief Fund established by the CARES Act of $2 million during the fourth quarter of 2023 and $5.2 million during the fourth quarter of 2022.
公司於 2023 年第四季認列與《CARES 法案》所設立之醫療提供者紓困基金(Provider Relief Fund)相關的收入 200 萬美元;而 2022 年第四季為 520 萬美元。
Excluding income from the PRF for both periods as well as the unfavorable adjustment to PLGL of $5.9 million or [$0.05] per diluted share that was recorded in the fourth quarter of '22, adjusted EBITDA for the fourth quarter of '23 increased 11.9% over the prior year to $169.6 million, and adjusted income attributable to Acadia stockholders per diluted share was $0.85, up 13.3% from the prior year.
在兩個期間皆排除 PRF 收入,並排除 2022 年第四季所認列對 PLGL 的不利調整 590 萬美元(或每股稀釋後盈餘 [$0.05])後,2023 年第四季調整後 EBITDA 較去年同期成長 11.9% 至 1.696 億美元;每股稀釋後、歸屬於 Acadia 股東的調整後淨利為 0.85 美元,較去年同期成長 13.3%。
Consistent with previous periods, adjustment to income for the fourth quarter of 2023 include transaction, legal and other costs, loss on impairment, gain on sale of property and the related income tax effects of all items. Maintaining a strong financial position and disciplined capital allocation are top priorities for Acadia. As of December 31, 2023, we had $100.1 million in cash and cash equivalents and $516.5 million available under our $600 million revolving credit facility with a net leverage ratio of approximately 1.9x.
與先前期間一致,2023 年第四季的損益調整項目包括交易、法律及其他成本、減損損失、資產出售利益,以及所有項目相關的所得稅影響。維持強健的財務狀況與紀律性的資本配置,是 Acadia 的首要優先事項。截至 2023 年 12 月 31 日,我們持有現金及約當現金 1.001 億美元,並在 6 億美元循環信用額度下尚有 5.165 億美元可用,淨槓桿比率約為 1.9 倍。
As previously announced on January 19, 2024, we entered into an amended credit agreement with our lenders to increase our Term Loan A by $350 million. Also in January '24, we paid $400 million to settle 3 lawsuits in New Mexico previously disclosed.
如先前於 2024 年 1 月 19 日公告,我們與貸款銀行簽訂修訂後的信貸協議,將 A 期定期貸款(Term Loan A)增加 3.5 億美元。此外,在 2024 年 1 月,我們支付 4 億美元以和解先前已揭露、位於新墨西哥州的 3 起訴訟。
Moving on to our outlook for 2024. As noted in our press release, we established our 2024 guidance, which includes revenue in the range of $3.18 billion to $3.25 billion, adjusted EBITDA in the range of $730 million to $770 million, adjusted earnings per diluted share in the range of $3.40 to $3.70, and total bed additions, excluding acquisitions of approximately 1,200 beds.
接著談 2024 年展望。如同我們在新聞稿中所述,我們已建立 2024 年指引:營收介於 31.8 億至 32.5 億美元;調整後 EBITDA 介於 7.30 億至 7.70 億美元;每股稀釋後調整後盈餘介於 3.40 至 3.70 美元;以及(不含併購)總床位新增約 1,200 張。
We also established financial guidance for the first quarter of 2024 as follows: revenue in a range of $775 million to $785 million, adjusted EBITDA in a range of $170 million to $175 million, and adjusted earnings per diluted share in a range of $0.78 to $0.83.
我們也建立了 2024 年第一季的財務指引如下:營收介於 7.75 億至 7.85 億美元;調整後 EBITDA 介於 1.70 億至 1.75 億美元;每股稀釋後調整後盈餘介於 0.78 至 0.83 美元。
This guidance reflects our expectation that same-facility revenue growth will be driven by mid-single-digit growth for both revenue per day and patient days for the full year. Please note that our guidance includes onetime payments from a state of approximately $10 million or $0.09 per diluted share for the year, of which, approximately $7 million or $0.06 per diluted share was received in the first quarter of 2024.
此指引反映我們的預期:全年同店營收成長將由「每病患日營收」與「病患日數」兩者皆呈現中個位數成長所驅動。請注意,我們的指引包含來自某州的一次性付款,全年約 1,000 萬美元(或每股稀釋後 0.09 美元);其中約 700 萬美元(或每股稀釋後 0.06 美元)已於 2024 年第一季收取。
Also, as a reminder, the company's guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or nonrecurring legal settlements expense.
另外提醒,公司指引不包含任何未來併購、處分、交易、法律及其他成本,或一次性法律和解費用的影響。
With that, operator, we are ready to open the call for questions.
以上,接線員,我們準備開放提問。
Operator
Operator
(Operator Instructions)
(接線員指示)
Today's first question comes from Whit Mayo with Leerink Partners.
今天第一個問題來自 Leerink Partners 的 Whit Mayo。
Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst
Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst
Heather, just on the guidance, can you maybe frame for us what you're assuming inside that for start-up losses? And then also on corporate overhead this year, I don't think you're going to be investing as much as last year? And then if you could share any more details on the $10 million state payment. I presume that's just a state supplemental DPP like payment or something?
Heather,關於指引,你能否幫我們說明一下其中對新設據點啟動虧損(start-up losses)的假設?另外,今年在公司層級的管理費用(corporate overhead)方面,我想你們不會像去年一樣投入那麼多?以及你能否分享更多關於該州 1,000 萬美元付款的細節。我猜那只是州政府補充性的 DPP 類付款或類似項目?
Heather Dixon - CFO
Heather Dixon - CFO
I'll go maybe in reverse order. The $10 million state payment, you're correct. That is a onetime that split over 2 payments, DPP payments. In terms of corporate costs, we have seen -- in 2023, we did see those costs increase from the prior year, but we've seen that stabilize in Q4 of 2023. And we are starting to see our selective investments pay off, for example, investments we've made in quality, IT, managed care, marketing, many areas. We're starting to see those benefits to the business as a whole, specifically in the positive labor trends that we just talked about and also our continued ability to meet that growing demand and deliver quality care.
我可能倒過來回答。關於該州 1,000 萬美元的付款,你說得沒錯。那是一筆一次性款項,分成兩次支付的 DPP 付款。至於公司成本方面,2023 年我們確實看到相較前一年有所增加,但在 2023 年第四季已趨於穩定。我們也開始看到選擇性投資帶來回報,例如我們在品質、IT、保險合約管理(managed care)、行銷等多個領域的投資。我們開始看到這些效益反映在整體業務上,特別是我們剛提到的正向人力趨勢,以及我們持續滿足成長需求並提供高品質照護的能力。
Turning to 2024, we expect to continue to see operating leverage as we move throughout the year. And our expectation is that the corporate costs will stay relatively consistent and continue to moderate specifically as a percentage of revenue as we see sort of the continued leverage throughout the year.
展望 2024 年,我們預期在全年推進的過程中將持續看到營運槓桿效益。我們的預期是,公司層級成本將維持相對一致,並且隨著全年持續的槓桿效益,特別是以營收百分比來看,將繼續趨於緩和。
In terms of start-up costs, we expect the start-up costs will run in a similar range to 2023, probably around $20 million to $25 million for the full year and around $5 million to $6 million per quarter. They're not significantly higher really because of the back ending of the opening of the bed. So you'll see that probably increase a little bit per quarter. But that's what we're expecting for start-up costs.
就開辦成本而言,我們預期開辦成本將落在與 2023 年相近的區間,全年大約為 2,000 萬至 2,500 萬美元,每季約 500 萬至 600 萬美元。它們實際上不會顯著更高,主要是因為病床開放時點較偏向年底。因此你可能會看到每季略有增加。但這就是我們對開辦成本的預期。
Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst
Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst
Great. And my second question, Chris, just CMMI is launching a new behavioral pilot focused on what appears to be the integration of behavioral with primary care with some value-based care to it. I know it's early, but just any preliminary thoughts on your desire to participate in this program. We're seeing a lot more of these 1115 waiver plans approved from states as well. So just curious if you have any thoughts on both of those?
很好。我的第二個問題,Chris,CMMI 正在推出一個新的行為健康試點,重點似乎是將行為健康與基層照護整合,並帶有一些價值導向照護的元素。我知道現在還早,但想請教你對於是否有意願參與這個計畫,有沒有任何初步想法?我們也看到各州有更多 1115 豁免(waiver)計畫獲得核准。所以也想聽聽你對這兩者是否有任何看法?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. Thanks, Whit. I mean I'd say to start, I mean, just overall, we're really glad to see the announcement. I mean we're tracking it closely. But I think we're still largely in waiting mode here for a number of the key areas of additional detail from CMS. So a number of those details that would include the care model, the funding model, geographic participation, et cetera.
是的,謝謝你,Whit。我想先說,整體而言,我們很高興看到這項公告。我們正在密切追蹤。不過我認為,目前我們在多個關鍵領域仍大致處於等待 CMS 提供更多細節的狀態。這些細節包括照護模式、資金模式、參與地理範圍等等。
But overall, just the key details of the program are yet to be released. And we're eagerly awaiting those specifics. It is something that we would like to participate in, and we think that we have some really compelling capabilities and just eagerly, we'll continue to track and await those ongoing details that are to come.
但整體來說,該計畫的關鍵細節尚未公布。我們正熱切等待這些具體內容。這是我們希望參與的計畫,我們也認為自身具備一些非常有吸引力的能力;我們會持續追蹤並期待後續將公布的相關細節。
Operator
Operator
And our next question today comes from A.J. Rice, UBS.
我們今天的下一個問題來自 UBS 的 A.J. Rice。
Albert J. William Rice - Analyst
Albert J. William Rice - Analyst
Obviously, volumes have been an important part of the story. I guess there's 2 ways that you can be seeing volume growth, one from just continued growth in demand -- underlying demand, but also I know the industry has faced some constraints on staffing, and that seems to be easy now. I wonder if you could just give us a little flavor for what true underlying demand is trending? And how much some of the growth is happening just because you're getting more access to staffing to be able to take patients?
顯然,服務量一直是這個故事的重要部分。我想服務量成長大概有兩種方式:一種是需求持續成長——也就是基本面需求;另一種是我知道整個產業曾面臨人力配置的限制,而現在似乎比較容易了。我想請你們分享一下,真正的基本面需求趨勢如何?以及目前部分成長有多少只是因為你們在人力取得上更順利,因此能收治更多病人?
Heather Dixon - CFO
Heather Dixon - CFO
So I would say you're right, A.J., there's a mix of both. We're seeing the demand for our services continue to be very strong. That's certainly not slowing down. We're also benefiting from capacity additions that we've made over the last couple of years. So we have the ability to meet the demand, whether it's through capacity additions or fully owned de novos or JVs.
我會說你說得對,A.J.,兩者都有。我們看到對我們服務的需求持續非常強勁,這當然沒有放緩。我們也受惠於過去幾年所做的產能擴增。因此我們有能力滿足需求,不論是透過產能擴增、全資新設(de novos)或合資(JVs)。
And then we're starting to see our ability to optimize how we accept what's in coming and really make sure that we have patients accessing the facilities in the right way. You're right. We're also seeing improvement in the labor trends. That's certainly contributing to our ability to serve the patients. We're seeing that all of the investments that we've made and our ability to really begin to see stabilization and labor contribute to our ability to serve those beds.
此外,我們也開始看到我們有能力去最佳化我們如何承接進來的需求,並確保病人以正確的方式進入並使用這些設施。你說得對,我們也看到勞動力趨勢改善,這確實有助於我們服務病人。我們看到我們所做的所有投資,以及我們開始真正看到人力穩定化,這些都在提升我們服務這些病床的能力。
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
And A.J., this is Chris. I just add a couple of quick things on that. I just think overall, some of the recruiting practices that we put in place have also helped us to meet this volume that we're continuing to see. And now we expect that to remain the case throughout '24. Just a few initiatives that I might point out that I think are helping us attract talent in, but also retain talent. I mean, first of all, these investments that we continue to make in technology to improve patient care and employee safety have been extremely helpful as we've done employee engagement surveys as well.
A.J.,我是 Chris。我再補充幾點。我認為整體而言,我們所建立的一些招募作法也幫助我們因應持續看到的這些服務量。而我們預期這種情況會在 2024 年持續。我想指出幾項我認為有助於我們吸引人才、也有助於留才的措施。首先,我們持續在科技方面投資,以改善病人照護與員工安全;在我們進行員工敬業度調查時,這些投資也被證明非常有幫助。
I think the intentional onboarding and training for our clinical staff has also helped us significantly to that front, we've seen some real variation historically.
我認為,對臨床人員有意識地進行到職導入與訓練,也在這方面大幅幫助了我們;過去我們確實看到一些很大的差異。
And then I just think relentless focus on employee engagement in every facility, tracking it and measuring it and holding our operators accountable has also led to some real improvements on that front that have enabled us to meet the demand that you're referencing. So...
另外,我也認為,我們在每一家機構都持續不懈地聚焦員工敬業度,進行追蹤與衡量,並要求營運團隊負起責任,也帶來了實質改善,讓我們能夠滿足你所提到的需求。所以……
Albert J. William Rice - Analyst
Albert J. William Rice - Analyst
No, that's helpful. And maybe just a follow-on to that is I know you're commenting on the strength and the rate updates and so forth. I think in the 10-K, you typically provide some payer mix data, has that been across the board? And is it resulting in any shift? The growth you're seeing does it tend to be more Medicaid, commercial, even Medicare? Can you comment on any trend in payer mix you're seeing?
不,這很有幫助。也許接著問一下:我知道你們提到需求強勁、費率更新等等。我想在 10-K 裡你們通常會提供一些付款方組合(payer mix)資料;目前是否是全面性的變化?是否造成任何結構性轉移?你們看到的成長,是否更偏向 Medicaid、商業保險,甚至 Medicare?能否談談你們看到的付款方組合趨勢?
Heather Dixon - CFO
Heather Dixon - CFO
Yes, sure. A.J., I can give you a quick update on the payer mix. What you will see, whenever you see the 10-K, you're right, you'll see it this afternoon. You'll see a slight uptick in Medicaid as a mix percentage, it went from 54.3% to 56.8% as part of the mix. There's a couple of things I would say, driving that part of it is volume growth, where we've opened new facilities or new beds at expanded facilities. There is certainly more bed additions related to Medicaid, and that's driving some of the increase in the payer mix.
可以,當然。A.J.,我可以快速更新一下付款方組合。你說得對,你在 10-K 裡會看到,今天下午就會公布。你會看到 Medicaid 在組合占比上略有上升,從 54.3% 上升到 56.8%。我想有幾個因素在推動:其一是服務量成長,因為我們開設了新設施,或在擴建的設施中新增病床。確實有更多新增病床與 Medicaid 相關,這推升了付款方組合中 Medicaid 的占比。
And then we just continue to have strong demand there as we build referral resources and really talk about the relationships that we have there to make sure we can meet the demand. We continue to have really good support from our Medicaid payers historically. And on average, I would say our Medicaid rates have performed a little bit better than what we've seen in the historical trends, and that's certainly a part of the growth.
另外,隨著我們建立轉介來源並強化相關關係以確保能滿足需求,我們在那一端的需求仍然強勁。歷來我們持續獲得 Medicaid 付款方相當好的支持。平均而言,我會說我們的 Medicaid 費率表現略優於過往的歷史趨勢,這也確實是成長的一部分。
And then we have some incremental funding that comes through from the Medicaid facilities as they see sort of the need to really bolster the behavioral programs that they have. Medicare, we saw a little bit more normalized seasonality. Typically, that sort of declined a little bit in Q4, and that's kind of what's leading to the increase or part of it in Medicaid. And then certainly, our commercial business book is part of the seasonal decline from a specialty perspective in Q4.
此外,隨著 Medicaid 相關機構看到需要強化其行為健康方案,我們也獲得一些額外的增量資金。Medicare 方面,我們看到較為正常化的季節性;通常在第四季會略為下降,這也是 Medicaid 占比上升的原因之一。至於商業保險業務組合,從專科角度來看,第四季也有季節性下滑。
Operator
Operator
And our next question today comes from Brian Tanquilut with Jefferies.
我們今天的下一個問題來自 Jefferies 的 Brian Tanquilut。
Brian Gil Tanquilut - Senior Equity/Stock Analyst
Brian Gil Tanquilut - Senior Equity/Stock Analyst
Chris, maybe as I think about your comments about how we're in Phase IV of the opioid epidemic, or what sort of investment do you need to make or should we expect you to make in order to take further advantage of, I should say, the opportunities emerging from the continuation of this opioid crisis?
Chris,當我思考你提到我們正處於阿片類藥物(opioid)流行的第四階段時,為了進一步把握——我應該說——這場阿片危機持續所帶來的新機會,你們需要做哪些投資,或我們應該預期你們會做哪些投資?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. Thanks for the question, Brian. I mean, I think we've continued to invest, not only in pulling together a really strong team for our CTC business, but also just optimizing the facilities that we have. I think we've done an excellent job, and our team has done an excellent job this past year of significantly reducing the variations that we've seen in wait times as an example. We've made investments in advance of redetermination to make sure that we were ready.
是的,謝謝你的問題,Brian。我認為我們持續在投資,不僅是為我們的 CTC 業務打造一支非常強的團隊,也包括最佳化我們現有的設施。我認為我們做得非常好,而我們的團隊在過去一年也做得非常出色,例如大幅降低了我們在等候時間方面過去看到的差異。我們也在重新資格審查(redetermination)之前就先行投資,以確保我們已做好準備。
We had kiosks in place at each of these facilities that continue to be very beneficial for patients when they check in. They want to get in and out of our CTC clinics inside of 5 minutes. And the technology that we put in place with these kiosks enable them to do that. So I think that's been very beneficial as well.
我們在每一個設施都設置了自助報到機(kiosks),病人在報到時持續受益。他們希望在 5 分鐘內完成進出我們的 CTC 診所。我們透過這些自助機所導入的技術,讓他們能做到這一點。因此我認為這也非常有幫助。
But I think overall, our ability to coordinate across the company in advance of redetermining is one of the reasons that we've been able to navigate through that, particularly well this past year. And there are investments that we will make that I think are modest with respect to just ensuring that we have the right team, particularly to be able to handle many of these RFPs that we anticipate given the magnitude of the $50-plus million in opioid settlement dollars. So that's one area that I would call out.
但我認為整體而言,我們在重新資格審查之前就能在公司內部進行跨部門協調,是我們在過去一年能夠特別順利度過這段期間的原因之一。而我們也會進行一些我認為相對溫和的投資,以確保我們有合適的團隊,特別是能夠處理我們預期會出現的許多 RFP(徵求提案),因為阿片和解金額規模超過 5,000 萬美元。因此這是我會特別點出的其中一個領域。
There are also some things that we've considered from a technology standpoint, dispensing units for dispensing methadone, which is obviously DEA regulated and very precise dosing is critical. And so we've looked at some technology there as well. But none of these are significant investments that I would call out, and I would just call it continued optimization of the really strong operational job that this team has continued to deliver.
從技術角度來看,我們也考量了一些事項,例如用於發放美沙酮的自動發藥設備;這顯然受到 DEA 監管,而且精準劑量至關重要。因此,我們也在那方面評估了一些技術。不過,這些都不是我會特別點名的重大投資;我會把它歸類為持續優化——這個團隊一直以來所交付的、非常出色的營運成果。
Brian Gil Tanquilut - Senior Equity/Stock Analyst
Brian Gil Tanquilut - Senior Equity/Stock Analyst
That makes a lot of sense. And then maybe as I think about the fact that you're adding 1,200 beds this year, and I think you've got another 10,000 -- 1,000 or so next year. And then the Austin announcement, could we expect an uptick in sort of patient day growth going forward?
這很合理。接著,當我想到你們今年要新增 1,200 張床位,而且我想明年還有另外 10,000 -- 大約 1,000 張。再加上奧斯汀的公告,我們是否可以預期未來病人日(patient day)成長會有所上升?
Heather Dixon - CFO
Heather Dixon - CFO
I'll take that one. The patient day growth we've seen has been strong for the last quarter. We also are thinking about how it's going to trend for the fourth -- sorry, for the 4 quarters for next year. For '23, we saw an uptick for the full year to 5 -- just over 5%, 5.1%. And that's up from what we had seen in the previous years that we're sort of hovering around the 3% to 4% range, plus or minus.
我來回答這題。我們在上一季看到的病人日成長一直很強勁。我們也在思考它在第四——抱歉,是明年接下來 4 個季度的走勢。2023 年全年,我們看到病人日成長上升到 5——略高於 5%,為 5.1%。這高於前幾年我們大致徘徊在 3% 到 4% 區間(上下些許波動)的水準。
We do expect to see a continuation at that higher level for the patient days growth for the full year for 2024 in the mid-single digits. So maybe a direct answer to your question is yes, we do expect to see that sort of continue with that higher range, but pretty consistent with where we came in.
我們預期 2024 年全年病人日成長將在中個位數(mid-single digits),並延續在較高水準。因此,直接回答你的問題:是的,我們確實預期會在較高區間持續,但大致與我們目前的表現相當一致。
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. And one other thing I would just add, Brian, is that when we did the Investor Day, one of our goals was to lay out the significant ramp in bed growth that we anticipated from 570 beds in 2022 to 670 in 2023 and then really stepping up to what we had guided as 1,150 both this year and next year. And so we continue to feel very confident in our ability to deliver on that.
是的。另外我想補充一點,Brian,在我們舉辦投資人日(Investor Day)時,我們的目標之一是說明我們預期床位成長將顯著加速:從 2022 年的 570 張到 2023 年的 670 張,然後真正提升到我們所指引的今年與明年各 1,150 張。因此,我們仍然非常有信心能夠達成。
Obviously, we have -- I said in my opening remarks, a number of JV projects that we expect to come online this year, 3 in particular, the Ascension Seton facility in Austin, which is our second with Ascension. Henry Ford in Detroit, which is a particularly large facility, 192 beds there. And then we'll be opening a facility just outside of Denver with Intermountain, a 144-bed facility there later this year as well.
顯然,我們有——我在開場致詞中提到——多個合資(JV)專案預計今年啟用,特別是其中 3 個:奧斯汀的 Ascension Seton 設施,這是我們與 Ascension 的第二個合作;底特律的 Henry Ford,這是一個特別大型的設施,床位數為 192 張;以及我們也將在今年稍晚於丹佛近郊與 Intermountain 開設一個 144 床的設施。
And then there's a number of de novos that we have very strong visibility into from one that we're getting ready to open in Tampa, the Agave Ridge facility in Mesa, and then there's another facility in Madison, Wisconsin, with over 100 beds that we'll open later this year as well.
此外,我們也有多個新設(de novos)專案具備非常高的可視性,包括我們正準備在坦帕開幕的一個、位於梅薩(Mesa)的 Agave Ridge 設施,以及威斯康辛州麥迪遜的另一個超過 100 張床位的設施,也將在今年稍晚開幕。
We also have really strong visibility into our bed additions. And then our CTC de novos as well that I mentioned will ramp from 6 to 14 incremental this year as well. So all that in totality just continues to give us strong visibility into what we had previously laid out of 1,150, and we've guided to roughly 1,200 beds that we'll bring online this year.
我們對床位新增也有非常高的可視性。還有我提到的 CTC 新設(de novos)也將在今年把增量從 6 家提升到 14 家。因此,綜合來看,這些都讓我們對先前提出的 1,150 張床位目標保持高度可視性;而我們也指引今年大約會有 1,200 張床位上線。
Operator
Operator
And our next question comes from Kevin Fischbeck with Bank of America.
下一個問題來自美國銀行(Bank of America)的 Kevin Fischbeck。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
It sounds like you're making a lot of progress on labor. I guess, can you just tell us what labor expense growth you're expecting in the guidance for 2024?
聽起來你們在人力方面取得了很大進展。我想請問,在 2024 年的指引中,你們預期的人力費用成長是多少?
Heather Dixon - CFO
Heather Dixon - CFO
Yes, sure. No problem. So yes, we are pleased. We have seen some progress. If you think about base wage inflation, as we mentioned in sort of the first part of the call, we did see the continued decline, and we saw an improvement down below 5% base wage inflation for Q4 '23. We would expect for that managed level of wage inflation to continue during 2024.
好的,當然,沒問題。是的,我們很滿意,也確實看到一些進展。若看基本薪資通膨(base wage inflation),如同我們在電話會議前段提到的,我們看到它持續下降,且在 2023 年第四季改善到 5% 以下。我們預期這種受控的薪資通膨水準將在 2024 年持續。
We're really pleased with the investments we've made. We still have some pockets of challenges, but we've made investments in specific geographies, as you know, over the past year, and we've focused on the employee engagement initiatives that Chris has talked about.
我們對已投入的投資感到非常滿意。我們仍有一些挑戰的區塊,但如你所知,過去一年我們在特定地區進行了投資,並聚焦在 Chris 所談到的員工敬業度(employee engagement)倡議。
So we expect that, that base wage inflation will reflect that more normalized rate, and we'll continue to see the trends that we saw as we exited 2023. Just as a reminder, Q1, we had sort of -- or Q4 last year, we had a high watermark, and we've come down over 300 basis points to just below 5%.
因此,我們預期基本薪資通膨將反映較為正常化的水準,並且會延續我們在 2023 年底所看到的趨勢。提醒一下,第一季我們曾——或是去年第四季——出現一個高點(high watermark),而我們已經下降超過 300 個基點,降到略低於 5%。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
Okay. So this is kind of where you think the run rate is there's not like a step down from here to 3% or 4% in the near term?
了解。所以你們認為目前就是這個運行水準(run rate),短期內不會再從這裡階梯式下降到 3% 或 4%?
Heather Dixon - CFO
Heather Dixon - CFO
I wouldn't say in the near term that we would be expecting that. We'll see a little bit of just a normal quarterly cadence as we have merit increases, and we have some of the payroll tax resets that come in Q1. But apart from that, I would think this would be sort of the new normal rate for 2024.
我不會說短期內我們會預期那樣。我們會看到一些正常的季度節奏,例如績效調薪(merit increases),以及第一季會有部分薪資稅(payroll tax)重置。但除此之外,我認為這將會是 2024 年的新常態水準。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
And then it sounds like the Medicaid volume was relatively strong in Q4, but I just want to make sure any disruption at all from redeterminations?
另外,聽起來第四季 Medicaid 量相對強勁,但我想確認一下,重新認定(redeterminations)是否造成任何干擾?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Kevin, this is Chris. I'll take that. I mean, overall, I would say no. During the fourth quarter, we just continued to be pleased in the continuation of the same trends that we were seeing in the third quarter and really throughout the year. So we just don't see a significant impact on either patient volume or patient mix going forward.
Kevin,我是 Chris。我來回答。整體而言,我會說沒有。第四季我們只是持續對趨勢感到滿意,因為它延續了我們在第三季、以及幾乎全年所看到的相同趨勢。因此,我們不認為未來在病人量或病人組合上會有顯著影響。
I think the impact continues to be very consistent and manageable. I think we're -- we ended the year and said that we estimated that about 70% of our patients had completed redeterminations. And we, I think, continue to anticipate the process will run its course, and we'll largely complete our patient population by midway through the year by the end of the second quarter.
我認為影響一直非常一致且可控。我們在年底時表示,我們估計約 70% 的病人已完成重新認定。我想我們仍預期這個流程會走完,並在年中、也就是第二季末之前,讓我們的大部分病人族群完成。
And I just think that the experience that we're seeing is that our ability to secure alternate forms of coverage for our patients remains really strong. I mean, the vast majority of those patients that have lost coverage are resolving favorably within 30 days of a coverage notification, which is really consistent with what we saw in the third quarter. So just overall, we continue to be cautiously optimistic and think we're just going to continue to see a continuation of the trends from Q3.
而且我認為我們看到的經驗是:我們為病人取得替代保險覆蓋的能力仍然非常強。也就是說,絕大多數失去覆蓋的病人,會在收到覆蓋通知後 30 天內得到有利的解決,這與我們在第三季看到的情況非常一致。因此整體而言,我們仍保持審慎樂觀,並認為我們將持續看到第三季趨勢的延續。
Operator
Operator
And our next question comes from Scott Fidel with Stephens.
下一個問題來自 Stephens 的 Scott Fidel。
Scott J. Fidel - MD & Analyst
Scott J. Fidel - MD & Analyst
Just wanted to drill in a bit more on the rate increases that you've talked about in the mid-single digits. And just interested in terms of between the commercial and the Medicaid books. Would you say that both are generally trending in that mid-single-digit range or is there any variance? And then on the Medicaid side, I'm curious around what you're budgeting or assuming for FY '25 Medicaid rates as the cycle starts to kick in, in the back half of the year?
我想更深入了解你們提到的中個位數(mid-single digits)費率上調。想請教在商業保險與 Medicaid 兩個組合之間,你會說兩者大致都在中個位數區間趨勢一致嗎?還是存在差異?另外在 Medicaid 方面,我也想了解,當費率循環在下半年開始啟動時,你們對 2025 財年(FY '25)Medicaid 費率的預算或假設是什麼?
Heather Dixon - CFO
Heather Dixon - CFO
Let me take the first half of that. So in terms of the rate, what I would say is across the different payers and markets, of course, we have variation. It just depends on what the market is and sort of what the bed need is in those markets and a variety of factors. What we're expecting for the year is that mid-single-digit growth. And that, I would say, you always have some above, some below, but it's pretty consistent across the business lines, and it's pretty consistent across the payer lines. So nothing that I would think that we need to point out and sort of call out as a significant deviation from that. It's relatively consistent.
我先回答前半段。就費率而言,我會說在不同付款方(payers)與市場之間,當然會有差異;這取決於市場狀況、那些市場的床位需求,以及多種因素。我們對全年預期的是中個位數成長。我會說通常會有一些高於、一些低於,但在各業務線之間相當一致,在各付款方線別之間也相當一致。因此沒有什麼我認為需要特別指出、或稱得上顯著偏離的情況;整體相對一致。
As we think about the full year and specifically to your question for the back half, as usual, we don't have a lot of visibility into the second half of the year. We do have visibility into the first half and the strong rate growth that we're projecting, which is the mid-single-digit level. We have a significant portion of our contracts that are renewed in the second half of the year, and as we have seen those come through and sort of the conversations that we're having, we feel really good about the visibility we have for the first half of the year.
當我們思考全年、特別是你問到的下半年時,一如往常,我們對下半年沒有太多可視性。我們對上半年則有可視性,並且對我們所預測的強勁費率成長(也就是中個位數水準)有把握。我們有相當大一部分合約會在下半年續約;就我們目前看到的進展以及正在進行的對話而言,我們對上半年所掌握的可視性覺得非常好。
But we'll continue to watch and continue to have those conversations with payers and see how those go for the second half of the year before I'm able to really give you any specific information about, say, Medicaid or any other payers for the second half of the year.
但我們會持續觀察,並繼續與付款方進行這些對話,看看下半年進展如何;在我能夠真正就例如 Medicaid 或其他任何付款方在下半年的情況提供具體資訊之前,還需要再觀察一段時間。
Scott J. Fidel - MD & Analyst
Scott J. Fidel - MD & Analyst
Okay. Got it. And then just on my follow-up question. Just interested at from this current vantage point when thinking about the quarterly cadence of both EBITDA and operating cash flows, if there's any sort of unique items relative to 2024 that you'd want to call out? Or do you think that it's going to be largely a sort of normal seasonality to EBITDA and cash flows this year?
好的,了解。接著就我的追問,從目前這個角度來看,在思考 EBITDA 與營運現金流的季度節奏時,是否有任何相較於 2024 年的特殊項目需要特別指出?還是你認為今年 EBITDA 與現金流大致會呈現較為正常的季節性?
Heather Dixon - CFO
Heather Dixon - CFO
Yes. I mean I think the quarterly cadence will be relatively consistent with what we normally see from year-to-year. Obviously, calling out that a couple of years ago, we had some abnormalities. We do think Q1 will have the normal seasonality as we sort of begin the ramp from the holiday period from 2023, probably a little bit slower growth in volume from the first quarter as part of the normal cadence.
是的。我認為季度節奏會與我們通常逐年看到的情況相對一致。當然要特別提到的是,幾年前我們確實出現過一些異常。我們認為第一季會呈現正常的季節性,因為我們正從 2023 年假期期間後開始回升;作為正常節奏的一部分,第一季的量能成長可能會稍微慢一些。
And then you'll see, as I mentioned, that Q1 impact as we reset sort of payroll taxes at the beginning of the year from a cost perspective.
另外,如我提到的,從成本角度來看,第一季也會受到年初重新設定薪資稅的影響。
Q2 and Q3 usually look pretty similar. And then Q4, as you know, has a little bit of normal seasonality that comes through relating to the holidays and sort of the inpatient days. So that's what I would expect. I think Q4, probably we have that impact of normal seasonality, Q1 normal seasonality and then Q2 and Q3 look pretty similar.
第二季和第三季通常看起來相當類似。然後第四季,如你所知,會有一些正常的季節性影響,與假期以及住院天數等因素相關。因此我預期會是這樣:第四季可能會受到正常季節性的影響,第一季也有正常季節性,而第二季與第三季看起來會相當接近。
Operator
Operator
And our next question comes from Sarah James at Cantor Fitzgerald.
下一個問題來自 Cantor Fitzgerald 的 Sarah James。
Sarah Elizabeth James - Research Analyst
Sarah Elizabeth James - Research Analyst
I was hoping we could dive a little bit deeper into the technology advancements you're making. So when you talk about clinical efficiency and remote monitoring. How do you think about that changing the daily workflow or the efficiency of your clinical workers? Can they see more patients? Or how do you think about it? And then when you say remote monitoring, what type of devices are you talking about? Are you talking about like tablet and video camera-based remote nurses? Or are you talking more like RPM devices?
我希望我們能更深入談談你們正在推進的技術進展。當你們談到臨床效率與遠端監測時,你們如何看待這會改變臨床人員的日常工作流程或效率?他們能看更多病人嗎?你們怎麼思考?另外,當你說遠端監測時,你指的是哪類裝置?你是指像以平板與攝影機為基礎的遠端護理人員那種?還是更像 RPM(遠端病患監測)裝置?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Sarah, this is Chris. I'll take that. For the remote monitoring, we're effectively talking about not video but being able to track monitoring of the patients that are generally wearing a bracelet and we have a tablet where one of our staff is able to check on them at the appropriate time. As you know, for those that are danger to themselves or others, particularly our acute patients, we may have to do bed checks from a 5-minute duration to a 15-minute duration, and this really enables us to monitor that and to follow through and execute on those requirements. So that's been incredibly helpful as we've rolled that out to 53 facilities and as we also continue to roll out or EMR.
Sarah,我是 Chris。我來回答。關於遠端監測,我們實際上談的不是視訊,而是能夠追蹤病患的監測狀況;病患通常會配戴一個手環,我們有一台平板,讓我們的員工能在適當的時間查看他們。如你所知,對於可能危及自己或他人的病患,特別是我們的急性病患,我們可能需要以每 5 分鐘到每 15 分鐘的頻率進行床邊查核,而這項工具確實讓我們能夠監測並落實執行這些要求。因此,當我們已將其推廣到 53 家機構,並且也持續推進我們的 EMR(電子病歷)時,這帶來了極大的幫助。
We continue to see just really strong overall outcomes across the board. I would start with quality. We've seen really strong improvements in a number of just very important metrics, the metabolic screening, discharge planning, national quality metrics that will continue to be really important to payers going forward. And I think we continue to perform well ahead of the benchmark on restraint and seclusion, national quality measures as well, which is really important as these events are where both staff and patient injuries most frequently occur.
我們持續看到整體成果在各方面都非常強勁。我會先從品質談起。我們在多項非常重要的指標上看到顯著改善,包括代謝篩檢、出院規劃、以及全國品質指標;這些未來對付款方而言仍會非常重要。我們在約束與隔離(restraint and seclusion)方面也持續明顯優於基準,這同樣屬於全國品質衡量指標;而這點非常重要,因為這類事件最常發生員工與病患受傷。
So we're clearly seeing benefits just from a patient safety and compliance standpoint as well. We've seen upticks, as I said earlier, on employee satisfaction because clearly, clinicians in this day and age are trained on an EMR. They're not trained in paper. And so that is very dissatisfying when they come into our industry broadly, and there has not been historically the level of investment, as you know, relative to the Med-Surg facilities that we see in behavioral health across the board, not just Acadia. So I think our ability to make that happen has been very effective.
因此,從病患安全與合規的角度來看,我們顯然也看到了效益。正如我先前提到的,我們也看到員工滿意度提升,因為在現今,臨床人員受訓使用的是 EMR,而不是紙本;因此當他們進入我們這個產業(廣義而言)卻仍使用紙本時,會非常不滿。你也知道,相較於我們在醫療外科(Med-Surg)機構所看到的投資水準,行為健康領域整體(不只是 Acadia)在歷史上一直缺乏同等程度的投資。我認為我們能夠推動這件事,效果非常好。
And then I think just overall, the efficiency to your question, everything from utilization review to improve documentation quality from standardized charts, reducing paper storage cost, all of these things together all tie in to enabling us to serve our patients in a more quality-oriented and efficient manner and also keep our patients safe and our staff safe.
再來就你問到的效率面,我認為從利用審查(utilization review)、透過標準化病歷提升文件品質、降低紙本儲存成本等,各項因素加總起來,都有助於我們以更重視品質且更有效率的方式服務病患,同時也讓病患與員工更安全。
Operator
Operator
And our next question comes from Peter Chickering with Deutsche Bank.
下一個問題來自 Deutsche Bank 的 Peter Chickering。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Some quick ones here. What percent of revenues were CTC in the quarter, and if I think about growth of around 20%, is that in the ballpark? And also can you break out the growth from patients versus pricing that would be amazing?
這裡幾個快問。這一季 CTC 佔營收的百分比是多少?如果我用大約 20% 的成長來看,是否大致合理?另外,你能否拆分一下成長是來自病患量還是來自價格?那會非常有幫助。
Heather Dixon - CFO
Heather Dixon - CFO
Yes. So what you'll see -- Peter, it's Heather. You'll see later this afternoon sort of the revenue growth by business line, and CTC was just right at 20% -- just right under 20%. So pretty consistent with what we've seen in the previous quarters. For Q4, is that the breakout you're asking for, for Q4 volume versus rates? Or were you asking for -- or asking for 2024?
好的。你稍後今天下午會看到按業務線拆分的營收成長——Peter,我是 Heather。CTC 大約正好在 20% 左右——略低於 20%。因此與我們前幾季看到的情況相當一致。至於第四季,你想要的拆分是第四季的量(volume)對比費率(rates)嗎?還是你問的是——或是問 2024 年?
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Either would be lovely.
兩者都可以的話就太好了。
Heather Dixon - CFO
Heather Dixon - CFO
Okay. Great. So for 2023 Q4, we saw the growth in patient days of 2.9% on a same-facility basis. And then the revenue per patient day was 7.1% for 2023, Q4. And then for the full year 2024, we're expecting mid-single digits for both.
好的,太好了。以 2023 年第四季來看,我們在同院(same-facility)基礎下的病患日(patient days)成長為 2.9%。而 2023 年第四季的每病患日營收(revenue per patient day)為 7.1%。至於 2024 年全年,我們預期這兩項都會是中個位數成長(mid-single digits)。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Got it. And then so looking out at the fourth quarter with CTC at 20% implies the rest of the business is growing around 9%. So over sort of 2x the growth coming from CTC. I guess any color on what percent of your 12% EBITDA growth in the quarter came from CTC?
了解。那麼往前看,第四季 CTC 佔 20% 意味著其餘業務大約成長 9%。也就是說,約有超過 2 倍的成長來自 CTC。我想問的是,你們本季 12% 的 EBITDA 成長中,有多少比例是由 CTC 貢獻的?
Heather Dixon - CFO
Heather Dixon - CFO
No. I would just say that we continue to see EBITDA margins across those different business lines, relatively consistent. As you look at those from quarter-to-quarter and then across the business lines -- the only thing I would point out is our closures during 2023, we had a few closures and of those, there were 3 that were in the specialty business. So you'll see a little bit of differentiation there as you look at the revenue contribution by business line. But apart from that, pretty consistent.
沒有。我只能說,我們持續看到不同業務線的 EBITDA 利潤率大致一致。無論你從季度到季度,或跨業務線來看,整體都相對一致——我唯一要指出的是,我們在 2023 年有幾項關閉(closures),其中有 3 家是在專科業務(specialty business)。因此當你按業務線看營收貢獻時,會看到一些差異。但除此之外,整體相當一致。
Operator
Operator
This concludes today's question-and-answer session. I would like to turn the conference back over to Chris Hunter for closing remarks.
以上為今日的問答環節。接下來我想把電話會議交回 Chris Hunter 作結語。
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Thank you. Before we end the call, I just want to again thank our committed facility leaders, our clinicians and our over 23,000 dedicated employees across the country who have continued to just work tirelessly to meet the needs of patients in a safe and effective manner. We have a really strong foundation and a proven strategy for driving growth in delivering greater value to both the patients we serve and our shareholders.
謝謝。在結束電話會議之前,我想再次感謝我們盡責投入的各院所領導團隊、臨床人員,以及全國超過 23,000 名敬業的員工;你們持續不懈地努力,以安全且有效的方式滿足病患需求。我們擁有非常堅實的基礎,以及一套經驗證的策略,能夠推動成長,並為我們服務的病患與股東創造更大的價值。
Thank you all for being with us this morning, and thank you for your interest in Acadia. If you have any additional questions today, please don't hesitate to contact us directly. Have a great day.
感謝各位今天早上與會,也謝謝各位對 Acadia 的關注。如果你們今天還有任何其他問題,請隨時直接與我們聯繫。祝各位有美好的一天。
Operator
Operator
Thank you. This concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.
謝謝。今日電話會議到此結束。感謝各位出席今天的簡報。各位現在可以掛線,祝各位有美好的一天。